Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients

PurposeSeveral studies have found an association between peripheral inflammatory cells and outcome. However, no study has explored their impact specifically in elderly patients. We have retrospectively examined pretreatment peripheral neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR), and neutrophil/monocyte ratio (NMR) in 113 elderly breast cancer patients and correlated our findings with disease-free survival (DFS) and overall survival (OS).MethodsAll patients 65years diagnosed from 2004 to 2018 with locally advanced breast cancer were included and classified as high vs low NLR, PLR, LMR, and NMR based on previously identified cutoffs. Estimated 1-, 3-, and 5-year DFS and OS were compared by Chi square analysis.ResultsAmong 104 evaluable patients, only PLR was significantly associated with estimated 3-year DFS (85.1% vs 63.6%; P=0.04) and OS (89.3% vs 68.1%; P=0.03). Among 69 patients with three or more years of follow-up, PLR (P=0.05), absolute lymphocyte count (ALC) (P=0.01), polychemotherapy (P=0.04), number of comorbidities (P=0.02), polypharmacy (P=0.005), and clinical stage (P=0.03) were associated with 3-year DFS. Polypharmacy (OR 4.9; P=0.02) and ALC (OR 4.6; P=0.04) retained their significance in the multivariate analysis.ConclusionsWe have found an association between low PLR and longer DFS in elderly breast cancer patients that is in line with findings in patients with a wider range of ages. Our findings on NLR contrast with those of other studies, indicating a potential differential effect in elderly patients. In addition, the effect of polypharmacy on outcome in elderly patients warrants further investigation.